Novo Nordisk has been a topic of intense discussion recently due to numerous developments. The disappointing outcome from a clinical trial halted Zealand's stock, leading to a significant plunge in its value, with their CEO urging for a shift in focus away from the 'weight loss Olympics.' Despite this setback, Novo Nordisk reports a
10% sales growth, with its obesity care reaching
DKK 82B. Additionally, Hims And Hers showed a surge of 40% following a deal to sell Novo Nordisk obesity drugs, which also led to a partnership between both companies. Despite the stock's tumbling following warnings of sales hit this year, the shares rose by 8% with a 'solid' launch of their Wegovy obesity pill. The stocks also got a bump as Hims And Hers Health experienced an uptick following the Novo Nordisk
GLP-1 partnership resolution. Yet, the poor performance of its next-gen obesity shot compared to Lilly's tirzepatide saw the stocks tumble again. The expansion into Ireland is key to fighting off Eli Lilly, and experts are considering Novo Nordisk as a
Buy‑and‑Never‑Sell Obesity Stock. However, the stock is considered
undervalued and has recently experienced a crash. Opinions of the stock risk have been mixed among analysts
Novo Nordisk Stocks News Analytics from Tue, 29 Jul 2025 07:00:00 GMT to Sun, 08 Mar 2026 01:31:45 GMT -
Rating 2
- Innovation -3
- Information 7
- Rumor -6
